Filing Summary
Entity and period: The supplied filing is Organovo Holdings, Inc.’s unaudited Form 10-Q for the three months ended June 30, 2021, its fiscal first quarter of 2022. This does not match the request metadata naming Vivosim Labs, Inc.; investors should confirm the intended issuer. Amounts below are in U.S. dollars.
Business Context
Organovo describes itself as an early-stage biotechnology company using 3D human tissue models to identify drug targets and pursue drug discovery. Its initial focus is inflammatory bowel disease, including ulcerative colitis and Crohn’s disease. The filing reports no revenue for the quarter and says meaningful revenue is not expected in the foreseeable future.
Financial Results and Position
| Metric | Three months ended June 30, 2021 | Prior-year comparable period |
|---|---|---|
| Revenue | Not reported in the statements presented | Not reported in the statements presented |
| Research and development expense | $0.58 million | $0 |
| Selling, general and administrative expense | $1.98 million | $2.79 million |
| Total operating costs and expenses | $2.56 million | $2.79 million |
| Net loss | $2.53 million | $2.77 million |
| Net loss per share, basic and diluted | $0.29 | $0.40 |
| Cash used in operating activities | $1.41 million | $2.57 million |
At June 30, 2021, cash and cash equivalents were $36.01 million, with an additional $0.11 million of restricted cash. Current assets were $36.66 million and current liabilities were $0.96 million, yielding reported working capital of $35.7 million. Total assets were $38.29 million and stockholders’ equity was $37.33 million. The balance sheet presents no debt line item. Gross margin is not applicable based on the information presented, which shows no revenue.
Investing activities used $0.19 million, primarily for fixed-asset purchases; financing activities provided $0.25 million from common-stock issuance. Cash, cash equivalents and restricted cash declined $1.36 million during the quarter. The accumulated deficit was $298.82 million.
Changes Versus Prior Period
- R&D expense rose from zero as the company restarted research activity; management reported an average of five full-time R&D employees, versus none in the prior-year quarter.
- SG&A declined $0.81 million, or 29%, primarily amid lower headcount and stock-based compensation, partly offset by higher consulting costs.
- Net loss narrowed by $0.24 million, while operating cash use fell by approximately $1.16 million.
- The company issued 27,545 shares through its at-the-market program for approximately $0.25 million net proceeds. It reported approximately $28.3 million remaining under the ATM program.
Outlook, Risks and Unusual Items
- Management forecasts fiscal-year 2022 total operating expense of $13 million to $15 million and believes available cash can fund operations for at least 12 months. It expects R&D activity and associated expenses to increase.
- The company says additional capital will be needed to implement its drug-discovery strategy. Financing may be unavailable or unfavorable and could dilute shareholders; the filing reports $128.3 million available under its shelf registration statement.
- Cellink and related parties initiated inter partes review proceedings challenging two Organovo bioprinter patents. The company estimated IPR costs of $0.85 million to $0.95 million. It also disclosed a Cellink declaratory-judgment action, for which it said a loss was reasonably possible but not estimable, and a separate patent-infringement complaint filed by Organovo seeking injunctive relief and damages.
- COVID-19-related impacts remain uncertain, including possible effects on human-cell supply, research progress, partners and access to capital. Management said operations had not then been negatively affected.
- The filing highlights execution risks from an unproven business strategy, early-stage drug discovery, competition, dependence on key personnel and third-party suppliers, intellectual-property disputes, and potential conflicts involving Viscient Biosciences. The company reported no accrual for legal loss contingencies.
- Disclosure controls and procedures were assessed as effective at quarter-end; no material change in internal control over financial reporting was reported.
Important Facts to Verify
- Confirm the issuer and period: the filing is for Organovo Holdings, Inc. and the quarter ended June 30, 2021, notwithstanding the metadata identifying Vivosim Labs and 2021 Q1.
- Check the company’s current cash runway against the stated 12-month estimate, forecast expenses and planned R&D expansion.
- Track the status, outcome and costs of the Cellink patent proceedings and any related potential financial exposure.
- Review subsequent ATM or other securities issuance, remaining financing capacity and resulting shareholder dilution.
- Assess progress toward validated drug targets and partnerships; the filing reports no drug candidates developed under the new strategy and no meaningful near-term revenue expectation.